Archive for the ‘czech republic’ Category
The papers present a method for imaging very small things — like biological processes on a molecular scale — that could be an alternative to electron microscopy, as the authors explain in a video. But after the papers were published in the New Journal of Physics, last author Ulf Leonhardt, now based at the Weizmann Institute of Science, found out that some of the data
were pixel-by-pixel mirror-symmetric, which is impossible for genuine experimental data.
One of the researchers co-authored a subsequent paper that acknowledges one of the papers incorrectly assumed the data were symmetrical, and could therefore be extrapolated from one side to the other. A representative of the publisher told us they have not seen any signs of misconduct, and the problem seemed to result from a “series of apparent miscommunications between the authors.”
In the “counterstatement” to the 2015 paper, Christian Seip of the Rostock University in Germany said the paper — about the development of a Marine Spatial Data Infrastructure (MSDI) in Croatia — took content from his dissertation thesis, about MSDI geoportals in Germany.
In addition, Seip argued that the original paper, “A Framework for Evaluation of Marine Spatial Data Geoportals Using Case Studies,” in GeoScience Engineering (GSE) — shows “major weaknesses” and therefore “should have not been published even [if] it was not plagiarized.”
Seip told us: Read the rest of this entry »
Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.
The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.
A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.
Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:
Both retractions appeared in Biochemical and Biophysical Research Communications, one in October 2014 and one in January 2015. His story began two decades ago in 1994, when he published a paper in Nature that couldn’t be reproduced, and was eventually retracted in 2013.
The best part of the story, of course, is that when his university was attempting to recreate his experiments, Bezouška broke into a lab fridge to tamper with the experiments. Unbeknownst to him, he was caught on hidden camera. Read the rest of this entry »
Several months after a drug company cancelled development of a potential diabetes cure because it found evidence that a biotech they had recently acquired had committed misconduct in studies of the drug, two retractions of relevant studies have appeared.
The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had
uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.
The retractions are both of papers published in Diabetes Care in May 2014. Here’s the notice for “Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial:” Read the rest of this entry »
Karel Bezouška, a researcher who broke into a lab refrigerator to tamper with an investigation into his work, has nine retractions.
Here’s the retraction notice in Biochemistry for 2010’s “Cooperation between Subunits Is Essential for High-Affinity Binding of N-Acetyl-d-hexosamines to Dimeric Soluble and Dimeric Cellular Forms of Human CD69:” Read the rest of this entry »
Karel Bezouška, the scientist who tried to derail an investigation into his work by breaking into a lab refrigerator has had an eighth paper retracted.
Here’s the notice for “Synthetic N-Acetyl-d-glucosamine Based Fully Branched Tetrasaccharide, a Mimetic of the Endogenous Ligand for CD69, Activates CD69+ Killer Lymphocytes upon Dimerization via a Hydrophilic Flexible Linker:” Read the rest of this entry »
Here’s the notice for “Carboxylated calixarenes bind strongly to CD69 and protect CD69+ killer cells from suicidal cell death induced by tumor cell surface ligands,” which was first published in Bioorganic & Medicinal Chemistry in 2010: Read the rest of this entry »
Here’s the notice from Bioconjugate Chemistry for 2012’s “Dimerization of an Immunoactivating Peptide Derived from Mycobacterial hsp65 Using N-Hydroxysuccinimide Based Bifunctional Reagents Is Critical for Its Antitumor Properties:” Read the rest of this entry »
Karel Bezouška, who, as we noted last year “broke into a lab refrigerator so he could tamper with samples being used to try to replicate the experiments during the investigation,” has had his fourth paper retracted.
Here’s the notice, for “Synthesis of Multivalent Glycoconjugates Containing the Immunoactive LELTE Peptide: Effect of Glycosylation on Cellular Activation and Natural Killing by Human Peripheral Blood Mononuclear Cells,” in the Journal of the American Chemical Society (JACS): Read the rest of this entry »